Fluvastatin

Fluvastatin (brand name Lescol) is a synthetic derivative of lovastatin, developed in the mid-1980s. Like lovastatin, it is classified as a first-generation statin. Fluvastatin was first tested in humans in 1986 and received FDA approval in December 1993. Fluvastatin is marketed and sold by the Swiss pharmaceutical company Novartis. The patent for fluvastatin expired in 2011.

Fluvastatin is available in 20 and 40 mg capsules, and in an 80 mg extended release form. Patients usually begin with a 20 mg daily dose. The maximum recommended dose is 80 mg per day. Fluvastatin/Lescol are not widely used compared to atorvastatin/Lipitor, simvastatin/Zocor, and rosuvastatin/Crestor. Indeed, a recent check of a popular on-line pharmacy showed they did not even list fluvasatin on the website.

Recent research in Japan has found that fluvastatin can help healing in patients with arterial stents. There is also research in rats that suggests fluvastatin can help with slow the onset of osteoporosis in those with diabetes.

National Library of Medicine on Fluvastatin

Recent research in Japan has found that fluvastatin can help healing in patients with arterial stents. There is also research in rats that suggests fluvastatin can help with osteoporosis in those with diabetes.

National Library of Medicine on Fluvastatin